Cart
sales@molnova.com
Eflucimibe
CAS No. 202340-45-2
Eflucimibe( —— )
Catalog No. M34231 CAS No. 202340-45-2
Eflucimibe (L0081) is an acyl coenzyme A: cholesterol acyltransferase inhibitor for the treatment of cardiovascular disease and endocrine and metabolic disorders, and can be used to study atherosclerosis and hyperlipidemia.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 397 | In Stock |
|
| 5MG | 376 | In Stock |
|
| 10MG | 566 | In Stock |
|
| 25MG | 905 | In Stock |
|
| 50MG | 1200 | In Stock |
|
| 100MG | 1646 | In Stock |
|
| 200MG | 2223 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameEflucimibe
-
NoteResearch use only, not for human use.
-
Brief DescriptionEflucimibe (L0081) is an acyl coenzyme A: cholesterol acyltransferase inhibitor for the treatment of cardiovascular disease and endocrine and metabolic disorders, and can be used to study atherosclerosis and hyperlipidemia.
-
DescriptionEflucimibe (F 12511) is a new acyl-coenzyme A cholesterol O-acyltransferase (ACAT) inhibitor. Eflucimibe can be used in the research of atherosclerosis.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorAcyltransferase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number202340-45-2
-
Formula Weight469.72
-
Molecular FormulaC29H43NO2S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES[C@H](C(NC1=C(C)C(C)=C(O)C(C)=C1)=O)(SCCCCCCCCCCCC)C2=CC=CC=C2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Duloxetine
Duloxetine is an inhibitor of serotonin-norepinephrine reuptake(Ki of 4.6 nM),with treatment of major depressive disorder and generalized anxiety disorder.
-
Stressin I
Potent and selective corticotropin releasing factor receptor-1 (CRF1) agonist (Ki values are 1.5 and 224 nM for CRF1 and CRF2 receptors respectively). Increases ACTH levels and increases faecal pellet output in vivo following i.p. administration.
-
Activated Protein C ...
The peptide region containing residues 390-404 in Activated Protein C (APC) is essential for anticoagulant activity and is available for interaction with antibodies or with other proteins, such as the macromolecular substrates Factors Va or VIIIa. APC regulates blood coagulation by proteolytic inactivation of the blood coagulation cofactors Va and VIIIa.
